Ask for smart
bioprocess
ASKLEIA develops innovative biomolecule purification technologies combining precipitation and free flow electrophoresis — reducing production costs and enabling rapid implementation of biopharmaceutical production solutions at controlled costs.
Don't just ask for purity. Askleia it!
Technology Advantages
A continuous purification platform designed to simplify industrial reality
A continuous purification platform built around two integrated steps —
reducing costs, complexity and environmental footprint.
Our Technology
Two validated technology blocks
Y Serie
Selective Continuous Precipitation
Continuous precipitation and filtration
Continuous precipitation is achieved by micro-mixing the crude feedstock with a precipitating agent, followed by controlled separation of contaminants.
F Serie
Continuous Free-flow Electrophoresis
Industrial-scale free-flow separation
ASKLEIA's FFE chip enables continuous molecular separation based on electrophoretic mobility with reduced buffer consumption and strong specificity.
Technology Objective
Designed around the molecular problem, not the existing toolbox
ASKLEIA's approach is rooted in a deep understanding of the physicochemical properties governing biomolecule behaviour during separation. Rather than adapting existing purification hardware to new molecules, our technologies are engineered from first principles — targeting the specific binding, selectivity, and elution mechanisms that matter most for each molecule class.
This allows us to achieve high purity with significantly fewer operational steps, eliminating intermediate cleanup stages that add time, cost, and risk of loss.
Industrial Transferability
From lab innovation to manufacturable, transferable processes
ASKLEIA technologies are designed with industrial transferability as a core constraint. Every process decision is evaluated not only for scientific performance but also for practical implementability — equipment compatibility, regulatory readiness, raw material availability, and cost at volume.
The result is a purification platform that can be adopted by contract manufacturers and biopharma producers without the need for extensive infrastructure rebuild.
Platform logic
Two innovative purification steps
The ASKLEIA platform highlights the company's two innovative stages — purification by precipitation and purification by electrophoresis — while conventional filtration steps remain in the background of the process.
Industrial positioning
Adaptable, transferable and scalable
ASKLEIA's purification technologies are designed to answer the economic and operational constraints of industrial bioprocessing.
Selective Continuous Precipitation
ASKLEIA's purification platform replaces column chromatography with a simpler, more cost-effective system — significantly reducing CAPEX and OPEX for biopharmaceutical manufacturers.
Reduced environmental footprint
No solid phase means fewer consumables, less chemical waste, and a significantly greener production process — a tangible advantage for clients with ESG and sustainability commitments.
Enhanced purity through electrophoresis
Continuous free-flow electrophoresis enables superior molecular specificity, allowing higher purity levels and finer selectivity than conventional separation methods.
Contact :
Hours: 9 a.m. – 5 p.m., Monday to Friday
Phone: +33 4 42 01 90 59
Address: 510 Avenue de Jouques, Pôle Performance, Building C2, 13400 Aubagne